Akcea Therapeutics Revenue and Competitors

Boston, MA USA

Location

$751.3M

Total Funding

Biotech

Industry

Estimated Revenue & Valuation

  • Akcea Therapeutics's estimated annual revenue is currently $64.9M per year.(i)
  • 0
  • Akcea Therapeutics's total funding is $751.3M.

Employee Data

    00
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$5.2M67-45%$107.3MN/A
#2
$0.3M20%N/AN/A
#3
$5.1M336%N/AN/A
#4
$11.9M77-37%$312.8MN/A
#5
$0.9M60%N/AN/A
#6
$235M300-5%$340.9MN/A
#7
$45.9M237-7%$7.6MN/A
#8
$3.9M5035%N/AN/A
#9
$5.4M353%N/AN/A
#10
$1.6M100%N/AN/A
Add Company

Akcea Therapeutics is a development and commercialization company focused on helping patients with serious diseases. Our priority is to drive clinical program execution, understand patient and physician needs, prepare the market, create market access, and commercialize our products on a global basis. We are driven by knowing that patients depend on us. An affiliate of Ionis Pharmaceuticals and based in Kendall Square, Cambridge, Massachusetts, Akcea was founded with a robust portfolio of development-stage drugs covering multiple targets and disease states using advanced antisense therapeutics. Akcea is derived from the Greek word for value and worth. Something that has akcea () is not common, but precious and rare. Our name supports the value we are creating for physicians, patients and their families, and other key stakeholders as we seek to commercialize a robust portfolio of development-stage, advanced, antisense therapies for serious cardiometabolic lipid disorders. Our immediate focus is to drive our clinical programs forward through development to commercialization while building on the Isis standards of excellence. http://www.fiercebiotech.com/story/isis-launches-cardio-subsidiary-and-recruits-genzyme-vet-run-it/2015-01-07

keywords:N/A

$751.3M

Total Funding

N/A

Number of Employees

$64.9M

Revenue (est)

N/A

Employee Growth %

N/A

Valuation

N/A

Accelerator

Akcea Therapeutics's People

NameTitleEmail/Phone
1
Associate Director, Clinical OperationsReveal Email/Phone
2
Chief Medical OfficerReveal Email/Phone
3
Manager, SEC ReportingReveal Email/Phone
4
Senior Director Medical AffairsReveal Email/Phone
5
Field Medical Associate DirectorReveal Email/Phone
6
Rare Disease SpecialistReveal Email/Phone
7
Associate Director, CMC Technical ServicesReveal Email/Phone
8
VP Global MarketingReveal Email/Phone
9
CEOReveal Email/Phone
10
Rare Disease SpecialistReveal Email/Phone

Akcea Therapeutics News

2022-04-06 - 5AM Ventures Pumps Another $750 Million into Life Sciences ...

Soteropoulos was previously the chief executive officer of Akcea Therapeutics. She also held leadership roles at Moderna and Sanofi.

2022-04-06 - Avidity Biosciences Expands Role of Michael MacLean to Chief Financial and Chief Business Officer

... therapeutics called Antibody Oligonucleotide Conjugates (AOCs™), ... MacLean served as chief financial officer of Akcea Therapeutics,...

2022-03-30 - Global Oligonucleotide Therapy Market Report 2022 - Featuring Biogen, GlaxoSmithKline and Pfizer Among Others - ResearchAndMarkets.com

Sarepta Therapeutics Inc. Jazz Pharmaceuticals. Bausch & Lomb. Kastle Therapeutics. Akcea Therapeutics. Arrowhead Pharmaceuticals Inc.

2019-09-08 - Here's Why Akcea Therapeutics, Inc. (AKCA) Dropped -1.5%

In its most recent trading session, Akcea Therapeutics, Inc. (AKCA) dropped by -1.5% – here is what that looked like (as of 2019-08-23): ...

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$12.9M0N/A$163M
#2
$9.8M0N/A$39M
#3
$4.8M0N/AN/A
#4
$33.3M0N/A$15M
#5
$4.6M0N/A$38M